H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Vor Bio to $17.50 from $20 and keeps a Buy rating on the shares post the Q4 results. Vor had approximately $230.2M in cash and cash equivalents, which is sufficient to fund planned operations into 2025, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VOR:
- Vor Bio reports Q4 EPS (53c), consensus (60c)
- Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
- Vor Bio to Participate in Upcoming Investor Conferences
- First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
- Vor Bio presents clinical data from VBP101 Phase 1/2a study of trem-cel